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Abstract 
Human embryonic stem cells (hESC) offer great potential for pharmaceutical research 
and development and, potentially, for therapeutic use.  However, improvements in 
cell culture are urgently required to allow the scaleable production of large numbers 
of cells that maintain pluripotency.  Supplementing feeder-free conditions with either 
Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) or readily synthesised analogues of 
this compound maintains hESC pluripotency in the absence of exogenous cytokines.  
When the hESC lines SA121 or SA461 were maintained in feeder-free conditions 
with EHNA they displayed no reduction in stem cell-associated markers such as 
NANOG, OCT4 and SSEA 4 when compared to cells maintained in full feeder-free 
conditions that included exogenously added basic fibroblast growth factor (bFGF).   
Spontaneous differentiation was reversibly suppressed by the addition of EHNA, but 
EHNA did not limit efficient spontaneous or directed differentiation following its 
removal.   We conclude that EHNA or related compounds offers a viable alternative 
to exogenous cytokine addition in maintaining hESC cultures in a pluripotent state 
and might be a particularly useful replacement for bFGF for large scale or good 
manufacturing practise-compliant processes.  
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hESCs originate from the inner cell mass of the developing blastocyst and can be 
maintained in an undifferentiated state whilst remaining capable of differentiating to 
all cell types in the body [1,2]. They have huge potential as both research tools and for 
cell therapies. Furthermore, they offer great potential to revolutionise aspects of the 
drug discovery process [3-5]. For toxicology and drug efficacy studies, as well as for 
aspects of high-throughput and high-content screens, the widespread availability of 
large numbers of reproducibly defined populations of human cells would accelerate 
progress greatly. However, with the exception of certain white cells populations there 
remain substantial barriers to obtaining nucleated human cells in a routine, timely and 
cost-effective manner.  hESCs have the potential to overcome such barriers but a 
number of technical challenges need to be overcome before this might be achieved.  
These include means to sustain hESCs, preferably in feeder layer-free monolayer 
culture through many passages, as proliferating, undifferentiated cells that still remain 
pluripotent, as well as means to then induce their differentiation to cells displaying 
key proteomic and functional, as well as visual phenotypic, markers of freshly 
isolated human cell types.   Furthermore, aspects of quality assurance and control 
must be inbuilt to such programmes to ensure reproducibility.  Within such 
programmes, the identification of small molecule ligands that either maintain the 
undifferentiated state or promote coherent development either towards fully 
differentiated cells or to precursor populations committed to differentiate towards a 
specific germ layer may be of particular use as a means to replace complex and often 
ill-defined combinations of biological growth promoters and inhibitors derived either 
from supportive feeder cells or via exogenously provided admixtures. 
In efforts to identify such small molecule ligands that maintain the 
pluripotency of hESC lines we adopted a pair of distinct strategies. The first of these, 
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which will not be discussed further herein, was a series of high content screens 
employing libraries of small molecules, many of which were already known to have 
biological activity within various, diverse cellular signaling cascades.  The second 
employed a much smaller number of compounds known to target pathways already 
well established to modulate cellular growth and differentiation. To facilitate the high 
content screening programme and to link this to the more directed small molecule 
identification programme, initial key requirements were to ensure the viability of 
hESCs in feeder-free conditions and the ability to generate and maintain monolayer 
cultures of the cells (Figure 1). These were achieved for both the SA121 and SA461 
hESC lines [6] , supplied by Cellartis AB (Dundee, UK), on fibronectin-coated dishes 
with the use of a fully supportive medium that consisted of a 1:1 mixture of defined 
media [7] and conditioned VitrohES (VitroLife, Gothenburg, Sweden). Under these 
conditions both lines could be successfully passaged 1 in 4 using trypsin with routine 
addition of bFGF at a final concentration of 10ng/ml.  Importantly, hESCs grown in 
these feeder-free conditions expressed a number of undifferentiated stem cell 
markers, including the transcription factors OCT-4 and NANOG, as well as the cell 
surface proteins SSEA3, SSEA4, TRA-160 and TRA-180, but did not express a wide 
range of markers indicative of individual germ layer differentiation. Such a marker 
profile strongly indicated the maintenance of a pluripotent phenotype. Conversion to 
feeder-free, monolayer culture allowed scale up of cell production and the potential 
for automation in cell culture, both pre-requisites for the high content studies and 
large scale screens. Such monolayer-maintained cells are also far more suitable to 
assess the effectiveness of small molecule ligands in the induction of cellular 
differentiation circuits. By contrast, this modification failed to address the need for 
addition of bFGF, a biological that is extremely expensive to acquire at good 
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manufacturing practice (GMP) grade, a requirement for translation to any therapeutic 
use of hESC.  
 It is well established that growth and differentiation of many cell types is 
either modulated by or under the direct control of cyclic AMP levels [8-9]. Cyclic 
nucleotide phosphodiesterases (PDEs) are a large and complex family of intracellular 
proteins and are the key, and often the only, cellular mechanism to reduce 
intracellular cyclic AMP levels [8-10]. We thus sought to explore if either broad 
spectrum cyclic AMP PDE inhibitors or highly selective inhibitors of specific PDE 
subtypes might modulate hESC viability, growth or differentiation or either modulate 
or replace the requirement for bFGF in maintaining the pluripotency of these cells in 
feeder-free culture. Interestingly, Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), a 
previously described PDE2 inhibitor [11-13], was able to maintain expression of 
markers of pluripotency, in the absence of added bFGF, throughout extensive periods 
that involved multiple passaging steps. By contrast, in the absence of bFGF and 
without addition of EHNA, pluripotency markers such as OCT4 were greatly reduced 
and the cells displayed clearly observable signs of spontaneous differentiation.  
Importantly, maintenance of hESC pluripotency in the presence of EHNA did not 
lock cells into a state unable to differentiate upon removal of this supplement.  When 
cells grown in the EHNA-containing medium for more than 20 passages were allowed 
to differentiate passively by removal of EHNA and replacing fibronectin with gelatin 
in monolayer cultures containing 20% foetal calf serum, within 4 weeks a number of 
differentiation markers including PAX6 (ectoderm), alpha-feta protein (endoderm) 
and smooth muscle actin (mesoderm) were readily detected in the cultures.   This 
indicated that, at least in vitro, cells grown in EHNA for multiple passages retained 
functional pluripotency. .  However, the effect of EHNA was sufficiently robust that 
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when hESC were exposed to conditions that promoted neural differentiation, the 
continued addition of EHNA suppressed the induction of the neural marker PAX6 and 
maintained expression of pluripotency-associated markers including NANOG and 
OCT4.  
 These effects of EHNA were concentration-dependent but did not appear, 
however,  to reflect inhibition of PDE2 because neither a second selective PDE2 
inhibitor, BAY-60-7550 [13-14] nor the pan-PDE inhibitor, 3-isobutyl-1-
methylxanthine (IBMX) [14], were able to mimic the effects of EHNA when added to 
cultures undergoing passive differentiation.  Although EHNA is indeed an inhibitor of 
PDE2, it is perhaps better known as an inhibitor of the enzyme adenosine deaminase 
(ADA) [15]. Inhibition of ADA is anticipated to result in the accumulation of 
adenosine and deoxyadenosine and these compounds are known to have wide ranging 
effects on cells produced by a variety of mechanisms [16-21]. We also explored, 
therefore, whether other, structurally unrelated ADA inhibitors, including the highly 
potent inhibitor pentostatin [22-24] could mimic the effect of EHNA. Pentostatin, 
however, had no EHNA-like effects. Despite this lack of effect we also explored the 
potential role of phosphorylated metabolites of adenosine that might accumulate in 
the presence of an ADA inhibitor. The adenosine kinase inhibitor, ABT-702 was thus 
used in conjunction with EHNA. After 2 weeks under passive differentiation 
conditions the effects of EHNA were not ablated by the co-presence of ABT-702. 
Additionally, stimulation of the adenosine monophosphate regulated kinase (AMPK) 
with 5-aminoimidazole-4-carboxamide riboside (AICAR), a previously widely 
studied regulator of this enzyme [25-26] was unable to mimic the effect of EHNA. 
We have, therefore, been unable to provide evidence to suggest an important role for 
the phosphorylation of adenosine to the maintenance of pluripotency markers by 
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EHNA. Adenosine and related nucleotides are effectively exported from cells. It was 
thus possible that the effects of EHNA were mediated via export of accumulated 
adenosine that resulted in autocrine or paracrine activation of adenosine receptors of 
the G protein-coupled receptor class, that are expressed on the surface of many cell 
types [27]. However, each of subtype selective and non-selective adenosine receptor 
agonists and antagonists were unable to mimic or antagonise, respectively, the effects 
of EHNA. Finally, because a number of kinases and kinase-based cascades are known 
to influence stem cell function and survival [28-30] we also made preliminary efforts 
to investigate the possibility that EHNA might act through a previously undefined 
protein kinase-inhibitory action.  However, when EHNA at 30 μM, a concentration 
sufficient to produce all the features of the maintainance of pluripotency, was 
evaluated using the Protein Kinase Panel service of the MRC National Centre for 
Protein Kinase Screening (University of Dundee, UK) it was unable to inhibit 
significantly any of the 80 kinases within the panel.  These included GSK-3 [28], a 
number of ERK/MAPK pathway components [29] and fibroblast growth factor 
receptor [30], which have all previously been shown to be important for hESC 
pluripotency. As such, despite wide-ranging efforts to define the mechanism of action 
of EHNA to maintain hESC pluripotency this remains elusive, as is often the case 
with intact cell- and phenotype-based assays.  
As a means to begin to help to define the chemical requirements of EHNA-
mediated suppression of hESC differentiation and maintenance of pluripotency we 
embarked on a limited medicinal chemistry programme to understand the minimum 
structural requirements for function and to identify potential EHNA mimetics  
appropriate for cost-effective, large scale production. Over a series of more than 30 
compounds that were synthesised or purchased from commercial sources the EHNA-
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like activity failed to track with ADA inhibitory activity. Indeed, a number of 
compounds failed to display EHNA-like activity but were potent ADA inhibitors 
confirming, along with the lack of action of pentostatin, that ADA is not the key 
molecular target. However, a number of EHNA analogues and variants displayed 
essentially full EHNA-like activity as assessed by the ability to maintain expression of 
NANOG and prevent the development of expression of PAX6 as a marker of 
ectoderm development.  Other compounds were partial in effect in that they mimicked 
EHNA in only one of these two characteristics. Importantly for future development 
and practical use of compounds that maintain hESC pluripotency,  these studies have 
identified simplified compounds that can be synthesised in bulk at low cost, making 
them very attractive for large scale production and current-good manufacturing 
practice-compliant requirements for the production of hESC. 
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Figures and Figure Legends 
Figure 1 
Generation and maintainance of monolayer cultures of SA461 hESCs in feeder-
free conditions 
Colonies of SA461hESCs maintained on a mouse embryo fibroblast feeder layer (A) 
is compared with the same cells (B) after transfer to feeder free monolayer culture. 
See text for further details. 
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